open access

Vol 52, No 4 (2021)
Review article
Published online: 2021-08-31
Submitted: 2021-07-15
Accepted: 2021-07-21
Get Citation

Management of nodular lymphocyte-predominant Hodgkin lymphoma: recommendations and unresolved dilemmas

Ewa Paszkiewicz-Kozik1
DOI: 10.5603/AHP.2021.0060
·
Acta Haematol Pol 2021;52(4):314-319.
Affiliations
  1. Department of Lymphoid Malignancies, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Vol 52, No 4 (2021)
REVIEW ARTICLE
Published online: 2021-08-31
Submitted: 2021-07-15
Accepted: 2021-07-21

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare malignancy of young adults characterized by an indolent and recurrent course. Although relapses or transformation to aggressive B cell lymphoma can occur decades after the primary diagnosis, the prognosis of NLPHL is relatively good, with as much as a 90% 10-year overall survival rate. The rarity of NLPHL makes it difficult to conduct multicenter prospective studies to establish separate guidelines for the diagnosis and treatment of this disease.

Therefore, the recommendations for the treatment of NLPHL have for many years been the same as for classic Hodgkin lymphoma, except for early stages without risk factors. The registration of anti-CD20 monoclonal antibody for the treatment of CD20-positive B-cell lymphomas has opened up new perspectives for NLPHL patients. Modern and accurate histopathological examinations as well as imaging diagnostics, especially positron emission tomography/computed tomography has allowed a more precise distinction to be made between the indolent NLPHL and the transforming-to-aggressive lymphoma forms. This review is intended to provide readers with the clinical features, course, outcome and methods of standard treatment in patients with NLPHL. The author in particular wishes to draw attention to unresolved issues regarding standard management and also the use of active surveillance, anti-CD20 immunotherapy, less aggressive regimens of chemotherapy, and indications for new treatment options.

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare malignancy of young adults characterized by an indolent and recurrent course. Although relapses or transformation to aggressive B cell lymphoma can occur decades after the primary diagnosis, the prognosis of NLPHL is relatively good, with as much as a 90% 10-year overall survival rate. The rarity of NLPHL makes it difficult to conduct multicenter prospective studies to establish separate guidelines for the diagnosis and treatment of this disease.

Therefore, the recommendations for the treatment of NLPHL have for many years been the same as for classic Hodgkin lymphoma, except for early stages without risk factors. The registration of anti-CD20 monoclonal antibody for the treatment of CD20-positive B-cell lymphomas has opened up new perspectives for NLPHL patients. Modern and accurate histopathological examinations as well as imaging diagnostics, especially positron emission tomography/computed tomography has allowed a more precise distinction to be made between the indolent NLPHL and the transforming-to-aggressive lymphoma forms. This review is intended to provide readers with the clinical features, course, outcome and methods of standard treatment in patients with NLPHL. The author in particular wishes to draw attention to unresolved issues regarding standard management and also the use of active surveillance, anti-CD20 immunotherapy, less aggressive regimens of chemotherapy, and indications for new treatment options.

Get Citation

Keywords

NLPHL, radiotherapy, immunochemotherapy, new agents

About this article
Title

Management of nodular lymphocyte-predominant Hodgkin lymphoma: recommendations and unresolved dilemmas

Journal

Acta Haematologica Polonica

Issue

Vol 52, No 4 (2021)

Article type

Review article

Pages

314-319

Published online

2021-08-31

DOI

10.5603/AHP.2021.0060

Bibliographic record

Acta Haematol Pol 2021;52(4):314-319.

Keywords

NLPHL
radiotherapy
immunochemotherapy
new agents

Authors

Ewa Paszkiewicz-Kozik

References (37)
  1. Posthuma HLA, Zijlstra JM, Visser O, et al. Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993–2016. Br J Haematol. 2020; 189(1): 117–121.
  2. Eichenauer DA, Aleman BMP, André M, et al. ESMO Guidelines Committee. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv19–iv29.
  3. Krajowy Rejestr Nowotworów. http://onkologia.org.pl (01.06.2021).
  4. Hartmann S, Eichenauer DA. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology. 2020; 52(1): 142–153.
  5. Hartmann S, Eichenauer DA, Plütschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013; 122(26): 4246–4252.
  6. Nogová L, Reineke T, Brillant C, et al. German Hodgkin Study Group. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008; 26(3): 434–439.
  7. Lazarovici J, Dartigues P, Brice P, et al. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. Haematologica. 2015; 100(12): 1579–1586.
  8. Posthuma HLA, Zijlstra JM, Visser O, et al. Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016. Br J Haematol. 2020; 189(1): 117–121.
  9. Al-Mansour M, Connors JM, Gascoyne RD, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol. 2010; 28(5): 793–799.
  10. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf (01.06.2021).
  11. Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017; 130(4): 472–477.
  12. Cheson BD, Fisher RI, Barrington SF, et al. Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059–3068.
  13. Eichenauer DA, Plütschow A, Fuchs M, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol. 2015; 33(26): 2857–2862.
  14. Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010; 116(3): 631–639.
  15. Eichenauer DA. PET-2-Guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant hodgkin lymphoma: an analysis from the german hodgkin study group. In: Abstract book: 25th Congress of the European Hematology Association virtual edition 2020. HemaSphere, London 2020: 4.
  16. Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. Eur J Cancer. 2012; 48(11): 1700–1706.
  17. Prusila RE, Haapasaari KM, Marin K, et al. R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. Acta Oncol. 2018; 57(9): 1265–1267.
  18. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008; 111(1): 109–111.
  19. Eichenauer D, Pluetschow A, Schroeder L, et al. Relapsed nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the german hodgkin study group (GHSG). Blood. 2016; 128(22): 922.
  20. Appel BE, Chen L, Buxton AB, et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the children's oncology group. J Clin Oncol. 2016; 34(20): 2372–2379.
  21. Alonso C, Dutta SW, Mitra N, et al. Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival. Cancer Med. 2018; 7(4): 1118–1126.
  22. Parikh RR, Grossbard ML, Harrison LB, et al. Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival. Leuk Lymphoma. 2016; 57(2): 320–327.
  23. Shivarov V, Ivanova M. Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. Br J Haematol. 2018; 182(5): 727–730.
  24. Binkley MS, Rauf MS, Milgrom SA, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020; 135(26): 2365–2374.
  25. Borchmann S, Joffe E, Moskowitz CH, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019; 133(20): 2121–2129.
  26. Appel BE, Chen Lu, Buxton AB, et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the children's oncology group. J Clin Oncol. 2016; 34(20): 2372–2379.
  27. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011; 118(16): 4363–4365.
  28. Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014; 32(9): 912–918.
  29. Cencini E, Fabbri A, Bocchia M. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2017; 176(5): 831–833.
  30. Karuturi M, Hosing C, Fanale M, et al. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013; 19(6): 991–994.
  31. Eichenauer D, Plütschow A, Schröder L, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018; 132(14): 1519–1525.
  32. Akhtar S, Elhassan T, Edesa W, et al. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. Annals of Hematology. 2015; 95(1): 49–54.
  33. Vaes M, Bron D, Vugts DJ, et al. Safety and efficacy of radioimmunotherapy with 90yttrium-rituximab in patients with relapsed CD20+ B cell lymphoma: a feasibility study. J Cancer Sci Ther. 2012; 4(12): 394–400.
  34. Golstein SC, Muylle K, Vercruyssen M, et al. Long-term follow-up of 2 patients treated with Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. Eur J Haematol. 2018; 101(3): 415–417.
  35. Ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) (IRENO). https://clinicaltrials.gov/ct2/show/NCT02626884 (01.06.2021).
  36. Cheah CY, Mistry HE, Konoplev S, et al. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma. 2016; 57(8): 1974–1976.
  37. Siricilla M, Irwin L, Ferber A. A case of chemotherapy-refractory "THRLBCL like transformation of NLPHL" successfully treated with lenalidomide. Case Rep Oncol Med. 2018; 2018: 6137454.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl